A Phase 2 Study of ABSK043 Combined With Osimertinib
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbbisko Therapeutics Co, Ltd
About this trial
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Eligibility criteria
Qualifiers
Aged 18 or above, male or female.
Participants must understand and voluntarily participate in this study and must have been provided informed consent for study participation.
NSNLC confirmed by tissue or cytological pathology. NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology.
Diagnosed locally advanced or metastatic NSCLC
Disqualifiers
1. Histological or cytological examinations suggest that NSCLC squamous cells is the predominant histology, or contains small cell lung cancer, neuroendocrine carcinoma, etc.
Trial design
Treatments tested in this trial
- ABSK043 in combination with Osimertinib
Treatment groups
72 Participants
are divided into 1 treatment groupSponsors and collaborators
Abbisko Therapeutics Co, Ltd
Lead sponsor
AstraZeneca
Collaborator
Source ClinicalTrials.gov